有害胚系突变是高危个体接受胰腺监测时肿瘤进展的风险因素
在约翰霍普金斯医院胰腺癌筛查项目中,464名接受胰腺监测的高危个体中,119例携带已知胰腺癌易感基因有害胚系突变,345例符合家族史监测标准但未检出已知突变。对后者行二代测序又发现15例(4.3%)先前未识别的突变。胚系突变风险组(n=134)胰腺癌、高级别异型增生或影像学可疑特征的累积发生率显著高于家族风险组(n=330),胰腺癌风险比HR 2.85(95%CI 1.0-8.18,P=.05)。
要点
- 345例家族风险个体中15例(4.3%)检出先前未识别的胰腺癌易感基因突变。
- 胚系突变风险组(n=134)胰腺癌、高级别异型增生或可疑特征的累积发生率显著高于家族风险组(n=330)。
- 胰腺癌风险比HR 2.85(95%CI 1.0-8.18,P=.05),胚系突变组高于家族风险组。
核心结论
- 携带可识别胰腺癌易感基因有害胚系突变者的胰腺癌累积发生率显著高于有强家族史但未识别突变者。
- 对符合家族史胰腺监测标准者进行基因检测,可能更好地界定肿瘤进展风险最高的人群。
研究设计与样本
- 约翰霍普金斯医院胰腺癌筛查项目中464名接受胰腺监测的高危个体的比较研究。
- 119例携带已知胰腺癌易感基因有害胚系突变,345例符合家族史监测标准但未检出已知胚系突变。
- 对345例家族风险个体行二代测序识别先前未识别的胚系突变。
- 比较全部胚系突变携带者与未检出已知胚系突变队列的肿瘤进展风险,并校正竞争性死亡。
主要发现
- 345例家族风险个体中15例(4.3%)检出先前未识别的胰腺癌易感基因突变:ATM 9例、BRCA2 2例、BRCA1 1例、PALB2 1例、TP53 1例、CPA1 1例。
- 胚系突变风险组(n=134)胰腺癌、高级别异型增生或胰腺影像学可疑特征的累积发生率显著高于家族风险组(n=330)。
- 胰腺癌风险比HR 2.85(95%CI 1.0-8.18,P=.05),胚系突变风险组高于家族风险组。
临床怎么用
- 作者认为,对符合家族史胰腺监测标准者进行基因检测,可能更好地界定肿瘤进展风险最高的人群。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the risk of neoplastic progression by germline mutation status versus family history without a known germline mutation (familial risk) among individuals with an increased risk for pancreatic cancer who are undergoing surveillance. METHODS: Of 464 high-risk individuals in the Cancer of the Pancreas Screening program at Johns Hopkins Hospital who were undergoing pancreatic surveillance, 119 had a known deleterious germline mutation in a pancreatic cancer susceptibility gene; 345 met family history criteria for pancreatic surveillance but were not known to harbor a germline mutation. We used next-generation sequencing to identify previously unrecognized germline mutations among these 345 individuals. We compared the development of pancreatic cancer, high-grade dysplasia, or clinically worrisome features, adjusting for competing mortality, among all germline mutation carriers with the risk of progression in a cohort without a known germline mutation. RESULTS: Fifteen (4.3%) of 345 individuals classified as having familial risk had a previously unrecognized pancreatic cancer susceptibility gene mutation (nine that involved ATM, two BRCA2, one BRCA1, one PALB2, one TP53, and one CPA1). The cumulative incidence of pancreatic cancer, high-grade dysplasia, or worrisome features on pancreatic imaging was significantly higher in the germline mutation risk group (n = 134) than in the familial risk group (n = 330 [for pancreatic cancer, hazard ratio, 2.85; 95% CI, 1.0 to 8.18; P = .05]). CONCLUSION: The cumulative incidence of pancreatic cancer is significantly higher among individuals with an identifiable deleterious germline mutation in a pancreatic cancer susceptibility gene than it is among individuals with a strong family history but no identified mutation. Gene testing of individuals who meet criteria for pancreatic surveillance on the basis of their family history may better define those most at risk for neoplastic progression.
引用
- Abe T, Blackford AL, Tamura K, et al. Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance. J Clin Oncol. 2019. PMID: 30883245. doi:10.1200/JCO.18.01512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。